PT  - JOURNAL ARTICLE
AU  - Qinghe Liu
AU  - Zhicheng Liu
AU  - Junkai Zhu
AU  - Yuhao Zhu
AU  - Deqiang Li
AU  - Zefei Gao
AU  - Liuling Zhou
AU  - Yuanbo Tang
AU  - Xiang Zhang
AU  - Junyan Yang
AU  - Qiao Wang
TI  - Assessing the Global Tendency of COVID-19 Outbreak
AID  - 10.1101/2020.03.18.20038224
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.03.18.20038224
4099  - http://medrxiv.org/content/early/2020/05/26/2020.03.18.20038224.short
4100  - http://medrxiv.org/content/early/2020/05/26/2020.03.18.20038224.full
AB  - COVID-19 is now widely spreading around the world as a global pandemic. In this report, we estimated the global tendency of COVID-19 and analyzed the associated global epidemic risk, given that the status quo is continued without further measures being taken.Based on official data of confirmed and recovered cases until May 21, 2020, the results showed that the global R0, excluding China, was estimated to be 2.76 (95% CI: 2.57 – 2.95). The United States, Germany, Italy, and Spain have peak values over 100,000. Using dynamical model and cluster analysis, we partition the globe into four regional epicenters of the outbreak: Southeast Asia extending southward to Oceania, the Middle East, Western Europe, and North America. Among them, Western Europe would become the major center of the outbreak. The peak values in Germany, Italy, and Spain were estimated to be 228,000, 291,000, and 298,000, respectively. Based on the current control measures by May 21, 2020, the peak value in the United States will reach 2,114,000. The cumulative number of 51 mainly researched countries’ patients might finally attain 6,542,000 (95% CI: 4,772,000 – 40,735,000). We also estimated the diagnosis rate, recovery rate, and infection degree of each country or region, and used clustering algorithm to retrieve countries or regions with similar epidemic characteristics. Several suggestions have been proposed for countries or regions in different clusters.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding supportAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets and code used for the current study are available from the corresponding author on reasonable request. Example code used for the analysis is available on GitHub. https://github.com/epimath/cm-dag